Skip to main content

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

New Online Registration Required for Live Call to Ask Questions

Audio-Only Webcast Still Available on Concert’s Website

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update.

Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.65
+4.50 (2.24%)
AAPL  265.29
+1.41 (0.53%)
AMD  202.16
-0.92 (-0.45%)
BAC  53.21
+0.47 (0.89%)
GOOG  304.15
+1.33 (0.44%)
META  638.30
-0.99 (-0.15%)
MSFT  401.35
+4.49 (1.13%)
NVDA  189.00
+4.03 (2.18%)
ORCL  156.76
+2.79 (1.81%)
TSLA  414.68
+4.05 (0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.